In January 2025, the global pharmaceutical industry's investment and licensing activities demonstrated a strong interest in novel treatment methods and technologies.

In January 2025, the pharmaceutical collaborations and transactions showcased a diversified trend of development, ranging from multinational pharmaceutical corporations to startup biotech enterprises.

With the thriving development of the biopharmaceutical industry, January 2025 witnessed several significant financing events exceeding $100 million.

In January 2025, several companies announced collaborations with international pharmaceutical giants to launch a series of new drugs globally.

In January 2025, a series of collaborative agreements were successively reached in the field of antibody-based pharmaceuticals in China.

In January 2025, China’s innovative pharmaceutical sector continues to make its mark on the global stage.

In January 2025, several significant mergers and acquisitions (M&A) took place in the biopharmaceutical industry.

10.28-11.3, Global Pharmaceutical Investment, Financing and Deal Events Summary.

Summary of Global Pharmaceutical Licensing Agreements and Financing Events from September 16 to September 22.

This week, multinational pharmaceutical companies including Sanofi, Bayer, Gilead Sciences, Novo Nordisk, and Pfizer have been notably active.

This article will use Pfizer as an example to teach you how to quickly learn to read Pharma/Biotech financial reports.

Pathios Therapeutics Secures $25M in Series B Funding for Cancer Drug Development.